Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK

Neal D Shore¹, Ugo De Giorgi², Stephen J Freedland^{3

4}

Affiliations

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
³ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ The Durham VA Medical Center, Durham, North Carolina.

Editorial

Neal D Shore et al. J Urol. 2025 Jan.

. 2025 Jan;213(1):110-113.

doi: 10.1097/JU.0000000000004228. Epub 2024 Sep 3.

Neal D Shore¹, Ugo De Giorgi², Stephen J Freedland^{3

4}

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
³ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ The Durham VA Medical Center, Durham, North Carolina.

No abstract available

Keywords: EMBARK; enzalutamide; high-risk biochemical recurrence; prostate cancer.

Comment in

Editorial Comment.
Kronstedt S, Singer EA. Kronstedt S, et al. J Urol. 2025 Jan;213(1):113. doi: 10.1097/JU.0000000000004243. Epub 2024 Sep 27. J Urol. 2025. PMID: 39330871 No abstract available.

1. Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453-1465. doi: 10.1056/NEJMoa2303974 - DOI - PubMed
1. Freedland SJ, Gleave M, De Giorgi U, et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid. 2023;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251 - DOI - PubMed
1. Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the “PSA negative” patients. Cancer. 2003;98(11):2362-2367. doi: 10.1002/cncr.11821 - DOI - PubMed
1. Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205(1):22-29. doi: 10.1097/JU.0000000000001376 - DOI - PubMed
1. Shore ND, Antonarakis ES, Cookson MS, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate. 2020;80(6):527-544. doi: 10.1002/pros.23967 - DOI - PMC - PubMed